For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt

By Caroline A Milton, Prashanthan Sanders, P. Steele. 2001

2,549 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/695089978bd63794e7f3981c0b5f8c16d9292218

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

M. Valgimigli
R. Brindis
L. Fleisher
E. Braunwald
M. Hand
M. Sabatine
Peter K. Smith
P. O'Gara

Citations in the corpus

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) (2009, background): “Although clopidogrel in combination with ASA has been shown to reduce recurrent coronary events in the posthospitalized ACS population,(32,43,46) the response to clopidogrel varies among patients, and clopidogrel resistance has been observed.(43) Information is accumulating about the variations in t”
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, methodology): “The recommended minimum duration of DAPT in patients treated with first-generation DES, based primarily on observational data and one subgroup analysis, has been 12 months (9,51,97,104,105).”
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. (2005, methodology): “This finding is supported by results from nonrandomized comparisons in registries and in the Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) and Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE) trials,(35-38) and builds ”